OBJECTIVE: To assess the responses to ATG and cyclosporin combination in patients of aplastic anemia. METHODS: Twenty three (17M: 6F) patients of aplastic anemia (11 very severe aplastic anemia (VSAA) and 12 severe aplastic anemia (SAA), were administered antithymocyte globulin and cyclosporin. RESULTS: The median age of patents was 8 years (range 6-12 years). Three patients died within 2 months of therapy. Twenty children (11 SAA and 9 VSAA) were finally analysed. Six months after the start of treatment, 8/20 (40%) patients responded-2 complete (CR) and 6 partial responses (PR). At the end of 1 year; 2 patients maintained CR and seven patients continued PR (overall responders 45%). The response was better in SAA (54.5%) with 2 CR and 4 PR; than in VSAA (33%) with 3 PR . Eleven (55%) children were alive without response. One patient developed AML 13 months later. CONCLUSION: We conclude that antithymocyte globulin and cyclosporin combination is an effective treatment for aplastic anemia patients who are ineligible for bone marrow transplantation.
OBJECTIVE: To assess the responses to ATG and cyclosporin combination in patients of aplastic anemia. METHODS: Twenty three (17M: 6F) patients of aplastic anemia (11 very severe aplastic anemia (VSAA) and 12 severe aplastic anemia (SAA), were administered antithymocyte globulin and cyclosporin. RESULTS: The median age of patents was 8 years (range 6-12 years). Three patients died within 2 months of therapy. Twenty children (11 SAA and 9 VSAA) were finally analysed. Six months after the start of treatment, 8/20 (40%) patients responded-2 complete (CR) and 6 partial responses (PR). At the end of 1 year; 2 patients maintained CR and seven patients continued PR (overall responders 45%). The response was better in SAA (54.5%) with 2 CR and 4 PR; than in VSAA (33%) with 3 PR . Eleven (55%) children were alive without response. One patient developed AML 13 months later. CONCLUSION: We conclude that antithymocyte globulin and cyclosporin combination is an effective treatment for aplastic anemiapatients who are ineligible for bone marrow transplantation.
Authors: A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster Journal: Blood Date: 2000-03-15 Impact factor: 22.113
Authors: E Gluckman; H Esperou-Bourdeau; A Baruchel; M Boogaerts; J Briere; D Donadio; G Leverger; M Leporrier; J Reiffers; M Janvier Journal: Blood Date: 1992-05-15 Impact factor: 22.113
Authors: E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi Journal: Br J Haematol Date: 1999-11 Impact factor: 6.998
Authors: N Frickhofen; J P Kaltwasser; H Schrezenmeier; A Raghavachar; H G Vogt; F Herrmann; M Freund; P Meusers; A Salama; H Heimpel Journal: N Engl J Med Date: 1991-05-09 Impact factor: 91.245
Authors: S Kojima; S Hibi; Y Kosaka; M Yamamoto; M Tsuchida; H Mugishima; K Sugita; H Yabe; A Ohara; I Tsukimoto Journal: Blood Date: 2000-09-15 Impact factor: 22.113
Authors: A Bacigalupo; R Brand; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier Journal: Semin Hematol Date: 2000-01 Impact factor: 3.851
Authors: Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young Journal: Lancet Date: 2003-11-15 Impact factor: 79.321